IL-8 has emerged as a potent biomarker to predict ICI responses in patients, and its upstream role in neutrophil modulation and its pleiotropic pro-tumor effects make IL-8 and its receptors suitable therapeutic targets [16]. This evidence concerns the gene CXCL8 and neoplasm.